Roivant Sciences Ltd.

Roivant Sciences Ltd.

34.85
EUR
0.00
(0.00%)
-0.48EPS
23.39BMarket Cap
Feb 15Next Earn

Total Valuation

EUR

As of September 30, 2026, Roivant Sciences Ltd. carries a market capitalization of 23.39B, placing it among publicly traded companies globally. Its enterprise value stands at 23.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap23.39B
Enterprise Value23.98B

Important Dates

Roivant Sciences Ltd.'s next confirmed earnings release is scheduled for February 15, 2027.

Earnings Date2/15/2027

Share Statistics

As of September 30, 2026, Roivant Sciences Ltd. has 723.69M shares outstanding.

Shares Outstanding723.69M

Valuation Ratios

These figures are as of September 30, 2026.

PS Ratio633.65
P/FCF Ratio-811.02
P/OCF Ratio-715.39

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 661.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.98B versus a market cap of 23.39B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales661.55

Financial Position

As of September 30, 2026, Roivant Sciences Ltd. maintains a current ratio of 15.56, meaning it holds 15.6x the short-term assets needed to cover near-term liabilities.

Current Ratio15.56
Debt / EBITDA-0.17

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -6.86, reflecting losses generated across the asset base. The company generates approximately 49,772.26 in revenue per employee across its workforce of 728.25, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-6.86
Revenue Per Employee49,772.26
Employee Count728.25

Taxes

EUR

Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. recorded 92.07M in income tax expense. The company reported a pretax loss of -262.20M and -303.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax92.07M

Stock Price Statistics

EUR

As of the close on November 17, 2026, Roivant Sciences Ltd.'s stock has gained approximately 98.10% over the past 52 weeks. The 50-day moving average sits at 33.12, while the 200-day moving average is 28.36.

52-Week Price Change98.10%
50-Day Moving Average33.12
200-Day Moving Average28.36

Income Statement

EUR

Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. generated 36.25M in revenue and converted that into -303.82M in net income, yielding earnings per share of -0.48. EBITDA reached -490.05M, while operating income came in at -1.17B.

Revenue36.25M
Gross Profit32.14M
Operating Income-1.17B
Pretax Income-262.20M
Net Income-303.82M
EBITDA-490.05M
EBIT-492.28M
Earnings Per Share (EPS)-0.48

Balance Sheet

EUR

These figures are as of September 30, 2026.

Total Debt81.87M
Working Capital3.60B

Cash Flow

EUR

Roivant Sciences Ltd. produced -32.11M in operating cash flow over the twelve months ended September 30, 2026. After subtracting 2.69M in capital expenditures, free cash flow totaled -29.42M - equivalent to -0.04 per share.

Operating Cash Flow-32.11M
Capital Expenditures2.69M
Free Cash Flow-29.42M
FCF Per Share-0.04

Margins

Over the twelve months ended September 30, 2026, Roivant Sciences Ltd. posted a gross margin of 88.68, reflecting its pricing power and cost economics. The operating margin of -3,233.98 and net profit margin of -838.21 provide insight into operational efficiency.

Gross Margin88.68
Operating Margin-3,233.98
Pretax Margin-723.38
Profit Margin-838.21
EBITDA Margin-1,351.98

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Roivant Sciences Ltd. shareholders.

Shareholder Yield0.65
FCF Yield-0.12

Scores

As of September 30, 2026, Roivant Sciences Ltd. has an Altman Z-Score of 2.98, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.98